LINC00968 and breast carcinoma: After a series of in vivo and in vitro experiments, it can be said that overexpressed LINC00968 contributes in reducing drug resistance in breast cancer by silencing WNT2 via recruitment of HEY1 and in turn, the inhibition of the Wnt2/β-catenin signaling pathway (Fig. 8).